Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?


OverviewFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary


Brainstorm Cell Therapeutics is owned by 16.31% institutional investors, 15.98% insiders, and 67.71% retail investors. Blackrock is the largest institutional shareholder, holding 0.60% of BCLI shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics16.31%15.98%67.71%
SectorHealthcare Stocks 279.42%10.64%-190.05%
IndustryBiotech Stocks 64.05%10.69%25.27%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock386.41K0.60%$130.80K
Gunderson capital management25.95K0.41%$29.06K
Blackrock funding, inc. /de25.17K0.40%$28.19K
Liberty wealth management22.67K0.36%$25.39K
Weaver consulting group15.62K0.25%$17.50K
Northern trust112.36K0.17%$38.03K
Traynor capital management11.00K0.17%$12.21K
Raymond james & associates111.28K0.17%$37.67K
Raymond james financial5.16K0.08%$5.78K
Virtu financial49.59K0.08%$17.00K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gunderson capital management25.95K0.01%$29.06K
Weaver consulting group15.62K0.00%$17.50K
Liberty wealth management22.67K0.00%$25.39K
Virtu financial49.59K0.00%$17.00K
Traynor capital management11.00K0.00%$12.21K
Institutional & family asset management6.00K0.00%$2.03K
Activest wealth management334.000.00%$374.00
Harbour investments3.56K0.00%$3.99K
Gsa capital partners llp---
Bogart wealth2.00-$2.00

Top Buyers

HolderShares% AssetsChange
Northern trust112.36K-57.57K
Virtu financial49.59K0.00%49.59K
Gunderson capital management25.95K0.01%25.95K
Traynor capital management11.00K0.00%11.00K
Lpl financial10.05K-10.05K

Top Sellers

HolderShares% AssetsChange
Vanguard group---1.51M
Armistice capital---690.67K
Geode capital management---682.82K
Abner herrman & brock---145.50K
State street---117.26K

New Positions

HolderShares% AssetsChangeValue
Gunderson capital management25.95K0.01%25.95K$29.06K
Traynor capital management11.00K0.00%11.00K$12.21K
Lpl financial10.05K-10.05K$3.40K
Raymond james financial5.16K-5.16K$5.78K
Harbour investments3.56K0.00%3.56K$3.99K

Sold Out

HolderChange
Mark sheptoff financial planning-100.00
Corecap advisors-133.00
Tower research capital llc (trc)-135.00
Eversource wealth advisors-141.00
Northwestern mutual wealth management-161.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202531-3.13%866,078238.80%1670.37%12-29.41%3-78.57%
Dec 31, 20244-89.19%48,928-99.55%-0.40%1-90.00%2-77.78%
Sep 30, 202437-26.00%10,822,353-10.37%154.37%10-52.38%9-
Jun 30, 2024504.17%12,075,121210.89%1851.82%2175.00%9-18.18%
Mar 31, 202448-4.00%3,884,1112.17%57.70%12-29.41%11-8.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.06M1.33%-2.00
Vanguard Total Stock Mkt Idx Inv22.14K0.39%-28.58K
Fidelity Extended Market Index31.41K0.32%-
Vanguard Institutional Extnd Mkt Idx Tr26.73K0.27%-
Fidelity Total Market Index9.56K0.10%-
Fidelity Series Total Market Index7.98K0.08%-
BlackRock Extended Equity Market K62.75K0.08%-27.00
Northern Trust Extended Eq Market Idx5.32K0.05%-
NT Ext Equity Mkt Idx Fd - L5.32K0.05%-
Spartan Extended Market Index Pool E3.28K0.05%239.00

Recent Insider Transactions


DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends


DateBuySell
2025 Q1--
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--

BCLI Ownership FAQ


Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 16.31%, followed by 15.98% insiders and 67.71% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 64.05%, which Brainstorm Cell Therapeutics falls below.

Who owns the most shares of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics’s largest shareholders are Blackrock (386.41K shares, 0.60%), Gunderson capital management (25.95K shares, 0.41%), and Blackrock funding, inc. /de (25.17K shares, 0.40%). Together, they hold 1.40% of Brainstorm Cell Therapeutics’s total shares outstanding.

Does Blackrock own Brainstorm Cell Therapeutics?

Yes, BlackRock owns 0.60% of Brainstorm Cell Therapeutics, totaling 386.41K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 130.8K$. In the last quarter, BlackRock decreased its holdings by -103K shares, a -21.03% change.

Who is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested?

Gunderson capital management is Brainstorm Cell Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.01% of its assets in 25.95K Brainstorm Cell Therapeutics shares, valued at 29.06K$.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 1.06M Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools